Do you want to read an article? Please log in or register.
Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland
Multiple Sclerosis
Related content
Multiple Sclerosis
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
PLoS One.
Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G
doi: 10.1371/
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
RECOMMENDED
Multiple Sclerosis
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
Ther Adv Neurol Disord.
Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A
doi: 10.1177/
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
Multiple Sclerosis
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)
doi: 10.1111/ene.13594.
Multiple Sclerosis
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
Eur J Neurol.
Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J
doi: 10.1111/ene.13936.
RECOMMENDED
Multiple Sclerosis
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
Mult Scler.
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R
doi: 10.1177/1352458519881761.
COMMENTED
Multiple Sclerosis
The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research
BMC Neurol.
Steinemann N, Kuhle J, Calabrese P, Kesselring J, Disanto G, Merkler D, Pot C, Ajdacic-Gross V, Rodgers S, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry
doi: 10.1186/s12883-018-1118-0.
RECOMMENDED
Multiple Sclerosis
Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
BMC Neurol.
Zecca C, Disanto G, Sacco R, Riccitelli GC, Gobbi C
doi: 10.1186/s12883-019-1383-6.